

HYFTOR™

(sirolimus topical gel) 0.2%

Now **Approved**





Nobelpharma

Nobelpharma develops medications and medical devices for underserved patient populations.

Nobelpharma America

Nobelpharma America, LLC is the first global subsidiary of Nobelpharma Co. Ltd., headquartered in Tokyo, Japan. Nobelpharma develops critical but neglected pharmaceuticals and medical devices.



U.S. Headquarters

4520 East-West Highway, Suite 400
Bethesda, MD 20814



Global Net Sales

150 Million USD (FY 2020)



Employees

Global **340+**



U.S. Leadership

Yoshiki Kida


President & CEO

Nobelpharma America, LLC

History

Nobelpharma was founded in 2003 in Tokyo, Japan and received its first drug approval in Japan in 2008. Since then, Nobelpharma has received approvals for 20 drugs and devices in Japan across a wide range of indications, bringing life-changing treatments to patients, caregivers and health care providers.

Our company name comes from Alfred Nobel, the founder of the Nobel Prize. We are proud to be part of Alfred Nobel's innovative and scientific legacy. His groundbreaking achievements continue to inspire our company's mission and values.



“We chose Bethesda, Maryland for our American headquarters because of the proximity to leading U.S. researchers, regulators, and advocacy groups. We look forward to working closely with these organizations to help improve the lives of people living with diseases that have little or no other treatment options.”

Yoshiki Kida, President & CEO of
Nobelpharma America, LLC